It has been reported that the Down syndrome occurs more often than expected among relatives of individuals with Alzheimer disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
In recent years, it has been possible for patients with Down syndrome to live longer with advanced medical treatment and social support. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia is seen earlier and more often in patients with Down syndrome (DS) than in the general population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The diagnostic significance of tau proteins in cerebrospinal fluids (CSF) has been described in many cases of dementia of Alzheimer type (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Physical Examination.—Physical examination revealed that the patient was well developed, but poorly nourished, with an appearance of chronic illness. 1 key finding →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The findings demonstrate five central negative conditions of precarity that older people had to manage: (a) loss and discontinuity of home-based healthcare services, (b) stress after loss or disruption of social support, (c) problems of poverty, (d) cognitive impairment and declining health and (e) stress of eviction. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26/100
The fall caused a sprained wrist and significant bruising to her hip, and although her scrapes and bruises healed, she was left with an overwhelming fear of falling again. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The project exposes a discrepancy between the manner in which the nursing staff perceive use of restraints in an idealistic situation and in a realistic situation and the greater tendency to use restraints in the realistic situation than in the idealistic situation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In Japan, dementia-related medical services are covered by the universal health insurance system, with patient co-payments based on age and income. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evercare recently rolled out its Medicare Advantage special needs plan designed specifically for people with chronic disease and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
26/100
Anticholinergic medications (ACh) are frequently prescribed to older adults despite being associated with impaired physical functioning. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Individuals living alone with dementia are rising rapidly, yet this group remains largely unrecognized in dementia care planning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Preliminary findings suggest these adaptations improved nursing assistant engagement, consistency in strategy use, and resident interaction quality. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The disease-related mortality from chronic non-communicable diseases is an emerging issue of global health in middle to high income countries. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Eine von 5 Frauen und einer von 10 Männern entwickeln eine Demenz vom Alzheimer-Typ, erläutern Palmqvist et al. zu Beginn ihrer Studie [1]. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Yeni bilimsel araştırma, Alzheimer hastalığının %90’ından fazlasının APOE geniyle bağlantılı olabileceğini ortaya koydu. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease is characterized by gradual and progressive neurodegeneration caused by neuronal cell death. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
La enfermedad de Alzheimer (EA) es la demencia neurodgenerativa más prevalente a nivel mundial, en los últimos años se ha resaltado su relación con los trastornos del sueño y la desregulación de la melatonina. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Im Zuge der Alzheimerkrankheit lagern sich Beta-Amyloid-Plaques im Gehirn ab. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nößler: Selten hat die Neuanführung eines Arzneimittels so ein großes Medienecho ausgelöst wie jüngst der Markteintritt von Lecanemab und jetzt die Zulassung von Donanemab. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Lecanemab ist eine Anti-Amyloid-Antikörper-Therapie, die entwickelt wurde, um toxische Amyloid-Plaques zu beseitigen und das Fortschreiten der Alzheimer-Krankheit zu verlangsamen. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Introdução: Avanços recentes na pesquisa de biomarcadores e estruturas diagnósticas, como o sistema de classificação ATN, redefiniram a abordagem do diagnóstico e tratamento precoces. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ResumenLa enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa crónica que se caracteriza por la acumulación excesiva de proteína beta-amiloide y de proteína Tau fosforilada. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
26/100
El Alzheimer es un trastorno neurodegenerativo que afecta la cognición y memoria. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →